News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • WhatsApp group of 500+ engineers is coordinating tunnel rescues after the Trishuli Valley flash flood.
  • Helicopters, excavators and heavy machinery are deployed to reach chambers under about 2.2 million tonnes of mud and debris.
  • Search teams use circulated tunnel drawings, phone lists and tactical advice to locate trapped workers.
  • Oil prices rose, with Brent near $95.67 and U.S. crude around $91.56, on U.S.-Iran clashes and shipping restrictions.
  • Oil is set for its biggest weekly advance since mid-July amid worries over prolonged Strait of Hormuz disruptions.
  • Micware unveils an AI-centered growth strategy to pivot from project work to scalable mobility and digital space platforms.

Latest Articles

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

Trevi Therapeutics, a clinical-stage biopharmaceutical company listed on Nasdaq (TRVI), announced acceptance of two abstracts for presentations at the ERS Congress 2026 in Barcelona. The presentations focus on quality-of-life outcomes from their Phase 2b CORAL and Phase 2a RIVER trials evaluating their investigational therapy, oral nalbuphine exten…

BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM

BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM

BridgeBio Pharma has initiated dosing of the first participant in ASCEND-ATTR, a Phase 3b/4 clinical study designed to assess the long-term effects of acoramidis, an oral transthyretin stabilizer, on cardiac structure, function, and amyloid burden in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Building on prior Phase 3 ATTRibute-C…

Abercrombie & Fitch Co. Reports Second Quarter Fiscal 2026 Results

Abercrombie & Fitch Co. Reports Second Quarter Fiscal 2026 Results

Abercrombie & Fitch Co. announced record net sales of $1.3 billion for Q2 fiscal 2026, marking the 15th consecutive quarter of growth with sales increases across all regions, led by an 8% rise in the Abercrombie brand. Operating margin reached 20%, and EPS was $4.17, outperforming prior outlook partly due to a $100 million IEEPA tariff refund benef…

Nexera Technologies: Subsidiary Fort Technology Closes Acquisition of Majority Stake in Logia USA to Fuel the Future of Data Centers

Nexera Technologies: Subsidiary Fort Technology Closes Acquisition of Majority Stake in Logia USA to Fuel the Future of Data Centers

Nexera Technologies announces that its majority-owned subsidiary Fort Technology has completed the acquisition of 50.1% of Logia USA, a company specializing in advanced fuel integrity solutions for data centers and other critical facilities in the US. This acquisition positions Fort Technology to capitalize on the growing data center market expecte…

Ondas: Real Top-Line Momentum — Trade It With Tight Risk Control

Ondas: Real Top-Line Momentum — Trade It With Tight Risk Control

Ondas (ONDS) is growing fast: recent contract wins and an acquisition lift 2026 revenue targets well into the hundreds of millions, yet the company remains unprofitable and cash flow negative. For traders willing to accept volatility, a defined long trade with a clear stop and target offers attractive asymmetric upside while limiting downside if ex…

Sezzle Anywhere + Sezzle Cash: Hidden Operating Leverage, Visible Upside

Sezzle Anywhere + Sezzle Cash: Hidden Operating Leverage, Visible Upside

Sezzle's merchant-facing Sezzle Anywhere checkout and consumer-facing Sezzle Cash product create a path to disproportionate EBITDA growth as volumes scale. The market appears to be underestimating operating leverage from higher take rates, fixed-cost absorption, and cross-sell between products. This trade targets the re-rating that should follow ac…

Arteris Building a Base Near $23 — Setup for a Mid-Stage Breakout

Arteris Building a Base Near $23 — Setup for a Mid-Stage Breakout

Arteris (AIP) has pulled back from its 52-week highs and is carving a consolidation base around $23. The company's steady wins in automotive and cybersecurity IP, plus a recent acquisition and expanded Arm partnership, give a fundamental backdrop for a swing trade. Valuation is lofty vs. current profitability, so the trade is price-action driven wi…

Ligand to Participate in September Investor Conferences

Ligand to Participate in September Investor Conferences

Ligand Pharmaceuticals announced that its senior management team will participate in key investor conferences in September 2026, including the Wells Fargo Healthcare Conference, Citi Biopharma Back to School Conference, and H.C. Wainwright Global Investment Conference. Management will conduct fireside chats and one-on-one meetings to discuss the co…

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

Radiopharm Theranostics has dosed the first patient in the second cohort of its Phase 1/2a clinical trial for RV-01 (177Lu-Betabart), a radiopharmaceutical targeting B7-H3 expressing solid tumors. The trial aims to evaluate safety, biodistribution, and preliminary anti-tumor efficacy, progressing after a positive safety recommendation. This marks a…

Auddia Announces LT350 CEO to be Interviewed on Fox Business’ Varney & Co. to Discuss Distributed Datacenter Strategy

Auddia Announces LT350 CEO to be Interviewed on Fox Business’ Varney & Co. to Discuss Distributed Datacenter Strategy

Auddia Inc. announced that its CEO, Jeff Thramann, will be interviewed on Fox Business' Varney & Co. to discuss the LT350 distributed datacenter strategy—a modular AI data center infrastructure integrated into parking lot canopies. Concurrently, Auddia plans to merge with Thramann Holdings to form McCarthy Finney, an AI native operating company, le…

Electra and Ontario Advance North America’s Critical Minerals Future with $17.5 Million Funding Agreement

Electra and Ontario Advance North America’s Critical Minerals Future with $17.5 Million Funding Agreement

Electra Battery Materials Corporation has finalized a C$17.5 million funding agreement with Invest Ontario to support the construction of North America's first cobalt sulfate refinery in Temiskaming Shores, Ontario. The refinery is expected to start commercial production by the fourth quarter of 2027, producing battery-grade cobalt sulfate and redu…

Senmiao Technology Limited Announces Name Change to Valor Energy Inc.

Senmiao Technology Limited Announces Name Change to Valor Energy Inc.

Senmiao Technology Limited has officially changed its name to Valor Energy Inc. and updated its Nasdaq ticker from AIHS to VAI. This rebranding signifies the company's strategic pivot from automobile-related services in China to developing digital infrastructure and energy projects in the U.S., focusing on AI and high-performance computing power-en…

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

INmune Bio has submitted regulatory filings to the European Medicines Agency seeking Orphan Drug Designation and scientific advice for Ebstrocel™, a pooled allogeneic umbilical cord-derived mesenchymal stromal cell therapy developed for recessive dystrophic epidermolysis bullosa (RDEB). These steps support the company’s planned EU Marketing Authori…

Photronics Reports Third Quarter 2026 Results

Photronics Reports Third Quarter 2026 Results

Photronics, Inc. reported its Q3 fiscal 2026 results, showing a 2.7% year-over-year revenue increase to $216 million, driven by recovering semiconductor design releases and strong fab utilization. IC revenue rose by 5%, while flat panel display revenue declined slightly. GAAP net income increased to $28.9 million ($0.49/share). The company remains …